Mark Berry

Mark Berry is an experienced epidemiologist with a robust background in public health research and data analysis. Currently, as the Director of Real World Evidence in Virology at Gilead Sciences, Mark oversees the global RWE strategy to support clinical development and post-authorization requirements. Previous roles include Health Research Senior Associate at Abt Associates, where Mark led COVID-19 studies for the CDC and managed program evaluations in HIV service delivery. Prior experience encompasses epidemiological positions at IQVIA and the Defense Health Agency, with significant contributions to health outcomes studies and large database management. Mark's career includes a strong focus on HIV prevention and treatment research during tenure at the CDC and lead roles in various biobehavioral surveys, contributing to PEPFAR initiatives. Mark holds a PhD in Epidemiology from the Johns Hopkins Bloomberg School of Public Health and an MPH from the University of Kansas Medical Center.